OGT develops optimised rare disease sequencing and analysis service
Oxford Gene Technology (OGT), a provider of innovative genetics research and biomarker solutions to advance molecular medicine, has extended its Genefficiency™ Sequencing Service to provide a dedicated service for investigating rare diseases. The specifically optimised version of the service will help investigators identify causative mutations quickly, easily and without the need for in-house technical or bioinformatics expertise. The data produced is of the highest possible quality thanks to OGT’s externally accredited laboratory procedures and quality control systems, while analysis is made easy using the company’s unique rare disease NGS software. The company hopes that the new bespoke, cost-effective service will help speed up research into those diseases that, due to their rarity, have not traditionally attracted extensive research efforts.
Employing a workflow that is specifically configured for analysing family trios and large patient cohorts, the Genefficiency Rare Disease Sequencing Service allows researchers to filter their data and rapidly identify genomic variations of interest. An integrated results report identifies affected genes and proteins and suggests possible disease associations, with even more information available via links to external databases. In this way, researchers can go from large complex data sets to biologically relevant findings with just a few clicks of a mouse button.
James Clough, Vice President Clinical & Genomic Solutions at OGT, commented: “Since we launched our new Genefficiency Targeted Sequencing Service last year, we have seen a lot of interest from researchers looking to investigate rare diseases using our sequencing offering. To meet this rising demand and make the genetic analysis of rare disease even easier, faster and more cost-effective, we have extended our service to offer a dedicated solution to these customers. Due to our high-throughput capabilities, we can process large sample cohorts in as little as eight weeks, while our innovative analysis platform allows users to concentrate on the biology of their study, rather than on sample processing, quality control and complex data analysis.”
OGT’s comprehensive service includes DNA enrichment using the Agilent SureSelect V4 or V4+UTR platforms, sequencing at 50x coverage on an Illumina HiSeq™2000 and expert data analysis using OGT’s software platform. OGT’s in-house bioinformatics team perform all the standard alignment and quality control processing that maximises data quality, as well as additional intelligent filtering of the information, a feature unique to OGT’s Genefficiency service. In addition to whole exome sequencing, targeted sequencing utilising OGT’s expertise in custom capture probe design is also available. To further ensure the success of each project, OGT provides users with expert consultancy at every stage, from initial experimental design through to providing clear, biologically relevant results. Perhaps most importantly, any researcher or clinician can now take advantage of next generation DNA analysis techniques, without the need for expensive in-house hardware, or internal technical and bioinformatics expertise.
To learn more about how the new rare disease sequencing service turns data into results, watch OGT’s latest video. Meet OGT at the International Congress on Research of Rare and Orphan Diseases, 29 February – 2 March 2012, Basel, Switzerland.
For more information about OGT’s range of genomic and biomarker solutions, visit the new OGT website at www.ogt.co.uk.
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park,
Sandy Lane, Yarnton, Oxford OX5 1PF
T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: products@ogt.co.uk ; W: www.ogt.co.uk
Notes for editors:
About Oxford Gene Technology
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative genetics research and biomarker solutions to advance molecular medicine. The company has two trading businesses: Genomics comprises of CytoSure™ cytogenetics array, labelling and interpretation software products and services for the detection of chromosomal abnormalities, and Genefficiency™ Genomic Services, a unique combination of platforms, expertise and processing capabilities to deliver rapid, relevant genomic data. The Biomarkers business utilises proprietary next generation technologies to build a rich patent-protected portfolio of promising biomarkers for early stage cancer detection including advanced programmes in colorectal and prostate cancer plus the autoimmune disease systemic lupus erythematosus.
CytoSure™ and Genefficiency™ NGS browser: For Research Use Only; Not for Use in Diagnostic Procedures
CytoSure: This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.
Find out more
For more information about any OGT product or service, please contact us.